Aron S Rosenstock1, Jiangong Niu2, Sharon H Giordano1,2, Hui Zhao2, Antonio C Wolff3, Mariana Chavez-MacGregor1,2. 1. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Abstract
BACKGROUND: Chemotherapy for early breast cancer is associated with a small risk of developing myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML). The aim of this study was to determine the risk of developing AML or MDS after modern adjuvant chemotherapy in older breast cancer patients and to further define the risk of individual chemotherapy regimens. METHODS: Patients diagnosed with stage I to III breast cancer from 2003 to 2009 were identified in the Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked databases. The development of AML/MDS, chemotherapy use, and comorbidities were identified with International Classification of Diseases, Ninth Revision and Healthcare Common Procedure Coding System codes. Analyses included descriptive statistics, cumulative incidences, and Cox proportional hazards models to estimate the hazard of AML/MDS after adjustments for clinically relevant covariates. RESULTS: In all, 92,110 patients were included; after a median follow-up of 85 months, the overall rates per 1000 person-years were 0.65 for AML and 1.56 for MDS. Patients who received an anthracycline (A) or anthracycline and taxane (A+T) regimen were more likely to develop AML (hazard ratio [HR] for A, 1.70; 95% confidence interval [CI], 1.16-2.50; HR for A+T, 1.68; 95% CI, 1.22-2.30) or MDS (HR for A, 2.18; 95% CI, 1.70-2.80; HR for A+T, 1.62; 95% CI, 1.29-2.03) than patients who did not receive chemotherapy. Patients using docetaxel and cyclophosphamide (TC) were not at increased risk for AML or MDS. CONCLUSIONS: Adjuvant chemotherapy is associated with a small but significant increase in the risk of AML and MDS, especially with regimens that include A. Longer follow-up is needed to confirm that risk is not increased with the recently adopted TC regimen. Cancer 2018;124:899-906.
BACKGROUND: Chemotherapy for early breast cancer is associated with a small risk of developing myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML). The aim of this study was to determine the risk of developing AML or MDS after modern adjuvant chemotherapy in older breast cancerpatients and to further define the risk of individual chemotherapy regimens. METHODS:Patients diagnosed with stage I to III breast cancer from 2003 to 2009 were identified in the Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked databases. The development of AML/MDS, chemotherapy use, and comorbidities were identified with International Classification of Diseases, Ninth Revision and Healthcare Common Procedure Coding System codes. Analyses included descriptive statistics, cumulative incidences, and Cox proportional hazards models to estimate the hazard of AML/MDS after adjustments for clinically relevant covariates. RESULTS: In all, 92,110 patients were included; after a median follow-up of 85 months, the overall rates per 1000 person-years were 0.65 for AML and 1.56 for MDS. Patients who received an anthracycline (A) or anthracycline and taxane (A+T) regimen were more likely to develop AML (hazard ratio [HR] for A, 1.70; 95% confidence interval [CI], 1.16-2.50; HR for A+T, 1.68; 95% CI, 1.22-2.30) or MDS (HR for A, 2.18; 95% CI, 1.70-2.80; HR for A+T, 1.62; 95% CI, 1.29-2.03) than patients who did not receive chemotherapy. Patients using docetaxel and cyclophosphamide (TC) were not at increased risk for AML or MDS. CONCLUSIONS: Adjuvant chemotherapy is associated with a small but significant increase in the risk of AML and MDS, especially with regimens that include A. Longer follow-up is needed to confirm that risk is not increased with the recently adopted TC regimen. Cancer 2018;124:899-906.
Authors: Gretchen G Kimmick; Bercedis L Peterson; Alice B Kornblith; Jeanne Mandelblatt; Jeffrey L Johnson; Judith Wheeler; Robin Heinze; Harvey J Cohen; Hyman B Muss Journal: J Clin Oncol Date: 2005-04-01 Impact factor: 44.544
Authors: Antonio C Wolff; Amanda L Blackford; Kala Visvanathan; Hope S Rugo; Beverly Moy; Lori J Goldstein; Keith Stockerl-Goldstein; Leigh Neumayer; Terry S Langbaum; Richard L Theriault; Melissa E Hughes; Jane C Weeks; Judith E Karp Journal: J Clin Oncol Date: 2014-12-22 Impact factor: 44.544
Authors: Rachel A Freedman; Jared C Foster; Drew K Seisler; Jacqueline M Lafky; Hyman B Muss; Harvey J Cohen; Jeanne Mandelblatt; Eric P Winer; Clifford A Hudis; Ann H Partridge; Lisa A Carey; Constance Cirrincione; Alvaro Moreno-Aspitia; Gretchen Kimmick; Aminah Jatoi; Arti Hurria Journal: J Clin Oncol Date: 2016-12-19 Impact factor: 44.544
Authors: Joanne L Blum; Patrick J Flynn; Greg Yothers; Lina Asmar; Charles E Geyer; Samuel A Jacobs; Nicholas J Robert; Judith O Hopkins; Joyce A O'Shaughnessy; Chau T Dang; Henry Leonidas Gómez; Louis Fehrenbacher; Svetislava J Vukelja; Alan P Lyss; Devchand Paul; Adam M Brufsky; Jong-Hyeon Jeong; Linda H Colangelo; Sandra M Swain; Eleftherios P Mamounas; Stephen E Jones; Norman Wolmark Journal: J Clin Oncol Date: 2017-04-11 Impact factor: 44.544
Authors: Hyman B Muss; Susan Woolf; Donald Berry; Constance Cirrincione; Raymond B Weiss; Daniel Budman; William C Wood; I Craig Henderson; Clifford Hudis; Eric Winer; Harvey Cohen; Judith Wheeler; Larry Norton Journal: JAMA Date: 2005-03-02 Impact factor: 56.272
Authors: Hyman B Muss; Donald A Berry; Constance Cirrincione; Daniel R Budman; I Craig Henderson; Marc L Citron; Larry Norton; Eric P Winer; Clifford A Hudis Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: Kamal Menghrajani; Alexandra Gomez-Arteaga; Rafael Madero-Marroquin; Mei-Jie Zhang; Khalid Bo-Subait; Jonathan Sanchez; Hai-Lin Wang; Mahmoud Aljurf; Amer Assal; Vera Ulrike Bacher; Sherif M Badawy; Nelli Bejanyan; Vijaya Raj Bhatt; Christopher Bredeson; Michael Byrne; Paul Castillo; Jan Cerny; Saurabh Chhabra; Stefan Octavian Ciurea; Zachariah DeFilipp; Nosha Farhadfar; Shahinaz Gadalla; Robert Peter Gale; Siddhartha Ganguly; Lohith Gowda; Michael R Grunwald; Shahrukh Hashmi; Gerhard Hildebrandt; Christopher G Kanakry; Ankit Kansagra; Farhad Khimani; Maxwell Krem; Hillard Lazarus; Hongtao Liu; Rodrigo Martino; Fotios V Michelis; Sunita Nathan; Taiga Nishihori; Richard Olsson; Ran Reshef; David Rizzieri; Jacob M Rowe; Bipin N Savani; Sachiko Seo; Akshay Sharma; Melhem Solh; Celalettin Ustun; Leo F Verdonck; Christopher Hourigan; Brenda Sandmaier; Mark Litzow; Partow Kebriaei; Daniel Weisdorf; Yanming Zhang; Martin S Tallman; Wael Saber Journal: Blood Adv Date: 2022-01-08
Authors: Leland Metheny; Natalie S Callander; Aric C Hall; Mei-Jei Zhang; Khalid Bo-Subait; Hai-Lin Wang; Vaibhav Agrawal; A Samer Al-Homsi; Amer Assal; Ulrike Bacher; Amer Beitinjaneh; Nelli Bejanyan; Vijaya Raj Bhatt; Chris Bredeson; Michael Byrne; Mitchell Cairo; Jan Cerny; Zachariah DeFilipp; Miguel Angel Diaz Perez; César O Freytes; Siddhartha Ganguly; Michael R Grunwald; Shahrukh Hashmi; Gerhard C Hildebrandt; Yoshihiro Inamoto; Christopher G Kanakry; Mohamed A Kharfan-Dabaja; Hillard M Lazarus; Jong Wook Lee; Sunita Nathan; Taiga Nishihori; Richard F Olsson; Olov Ringdén; David Rizzieri; Bipin N Savani; Mary Lynn Savoie; Sachiko Seo; Marjolein van der Poel; Leo F Verdonck; John L Wagner; Jean A Yared; Christopher S Hourigan; Partow Kebriaei; Mark Litzow; Brenda M Sandmaier; Wael Saber; Daniel Weisdorf; Marcos de Lima Journal: Transplant Cell Ther Date: 2021-08-21
Authors: Natalia Kunst; Shi-Yi Wang; Annette Hood; Sarah S Mougalian; Michael P DiGiovanna; Kerin Adelson; Lajos Pusztai Journal: JAMA Netw Open Date: 2020-11-02
Authors: Konstantinos V Floros; Sheeba Jacob; Richard Kurupi; Carter K Fairchild; Bin Hu; Madhavi Puchalapalli; Jennifer E Koblinski; Mikhail G Dozmorov; Sosipatros A Boikos; Maurizio Scaltriti; Anthony C Faber Journal: Cell Death Dis Date: 2021-02-15 Impact factor: 8.469